Amcenestrant in combination with CDK4/6 inhibitor palbociclib demonstrates synergistic anti-tumor activity in ER plus endocrine-resistant breast cancer xenograft models

被引：1

作者：

Shomali, Maysoun

Guo, Zhuyan

Cheng, Jane

Sullivan, Amy

El-Ahmad, Youssef

Sun, Fangxian

Sidhu, Sukhvinder

Lee, Joon Sang

Cai, Hui

Pollard, Jack

Debussche, Laurent

Soria, Chris

Bouaboula, Monsif

机构：

来源：

CANCER RESEARCH | 2022年 / 82卷 / 04期

关键词：

D O I：

10.1158/1538-7445.SABCS21-P4-02-08

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P4-02-08

引用

页数：2

共 50 条

[31] CDK4/6 inhibition directly enhances an anti-tumor immune response in breast cancer [J].

DeCristo, Molly J. ;

Goel, Shom ;

Watt, April C. ;

BrinJones, Haley ;

Sceneay, Jaclyn ;

Li, Ben ;

Ubellacker, Jessalyn M. ;

Xie, Shaozhen ;

Ramm, Susanne ;

Kim, Hye-Jung ;

McAllister, Sandra S. ;

Zhao, Jean J. .

CANCER RESEARCH, 2017, 77

[32] A novel CDK4/6 inhibitor combined with irradiation demonstrates potent anti-tumor efficacy in diffuse midline glioma [J].

Zuo, Pengcheng ;

Li, Yaopeng ;

Wang, Tantan ;

Lin, Xingyu ;

Wu, Zhen ;

Zhang, Junting ;

Liao, Xuebin ;

Zhang, Liwei .

JOURNAL OF NEURO-ONCOLOGY, 2023, 163 (01) :159-171

[33] A novel CDK4/6 inhibitor combined with irradiation demonstrates potent anti-tumor efficacy in diffuse midline glioma [J].

Pengcheng Zuo ;

Yaopeng Li ;

Tantan Wang ;

Xingyu Lin ;

Zhen Wu ;

Junting Zhang ;

Xuebin Liao ;

Liwei Zhang .

Journal of Neuro-Oncology, 2023, 163 :159-171

[34] Patterns of treatment and outcomes in real world elderly patients with metastatic oestrogen receptor positive (ER plus ) breast cancer receiving the CDK4/6 inhibitor Palbociclib and endocrine therapy [J].

Skrobo, D. ;

Prior, L. ;

Walshe, J. ;

Gullo, G. ;

Crown, J. .

EUROPEAN JOURNAL OF CANCER, 2020, 138 :S102-S103

[35] Bromodomain inhibition reduces CDK6 expression and reverses CDK4/6 inhibitor resistance in ER plus breast cancer [J].

Liu, Renyan ;

Pantelidou, Constantia ;

Jadhav, Heta ;

Shapiro, Geoffrey .

CANCER RESEARCH, 2022, 82 (12)

[36] β-catenin blockers enhance the effect of CDK4/6 inhibitors on stemness and proliferation suppression in endocrine-resistant breast cancer cells [J].

Ham, Ahrong ;

Cho, Min Hee ;

Won, Hye Sung ;

Jo, Jungmin ;

Lee, Kyoung Eun .

ONCOLOGY REPORTS, 2022, 48 (01)

[37] Publisher Correction: Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer [J].

Carla L. Alves ;

Sidse Ehmsen ;

Mikkel G. Terp ;

Neil Portman ;

Martina Tuttolomondo ;

Odd L. Gammelgaard ;

Monique F. Hundebøl ;

Kamila Kaminska ;

Lene E. Johansen ;

Martin Bak ;

Gabriella Honeth ;

Ana Bosch ;

Elgene Lim ;

Henrik J. Ditzel .

Nature Communications, 12

[38] Inhibition of GPX4 enhances CDK4/6 inhibitor and endocrine therapy activity in breast cancer [J].

Herrera-Abreu, M. T. ;

Guan, J. ;

Khalid, U. ;

Ning, J. ;

Costa, M. R. ;

Chan, J. ;

Li, Q. ;

Fortin, J-p. ;

Wong, W. R. ;

Perampalam, P. ;

Biton, A. ;

Sandoval, W. ;

Vijay, J. ;

Hafner, M. ;

Cutts, R. ;

Wilson, G. ;

Frankum, J. ;

Roumeliotis, T. I. ;

Alexander, J. ;

Hickman, O. ;

Brough, R. ;

Haider, S. ;

Choudhary, J. ;

Lord, C. J. ;

Swain, A. ;

Metcalfe, C. ;

Turner, N. C. .

NATURE COMMUNICATIONS, 2024, 15 (01)

[39] Gilteritinib Enhances Anti-Tumor Efficacy of CDK4/6 Inhibitor, Abemaciclib in Lung Cancer Cells [J].

Sun, Chao-Yue ;

Talukder, Milton ;

Cao, Di ;

Chen, Cun-Wu .

FRONTIERS IN PHARMACOLOGY, 2022, 13

[40] Anti-tumor activity of CDK2 inhibitor BLU-222 in combination with CDK4/6 inhibitors for overcoming resistance in HR positive and triple negative metastatic breast cancers models [J].

Luo, Linjie ;

Wang, Yan ;

Bui, Tuyen ;

Li, Mi ;

Kim, Serena ;

Navarro-Yepes, Juliana ;

Kettner, Nicole M. ;

Tripathy, Debasish ;

Hunt, Kelly K. ;

Faia, Kerrie ;

Keyomarsi, Khandan .

CANCER RESEARCH, 2024, 84 (06)

← 1 2 3 4 5 →